Biopharmaceutical company AstraZeneca has reached agreement with four European Union nations to supply up to 400 million doses of CCP virus vaccine by the end of 2020.
AstraZeneca, a drugmaker headquartered in Cambridge, England, struck the deal with Europe's Inclusive Vaccines Alliance to supply vaccines currently being tested by the University of Oxford to Germany, France, Italy, and the Netherlands "at no profit."
Oxford University is conducting phase 2 and phase 3 trials of the vaccine in about 10,000 adult volunteers.
The company has struck similar deals with the United Kingdom, the United States, the Coalition of Epidemic Preparedness Innovations, and Gavi the Vaccine Alliance, for 700 million doses.
"The most important finding to me is the combination of considerable efficacy in terms of viral load and subsequent pneumonia, but no evidence of immune-enhanced disease," professor Stephen Evans of the London School of Hygiene & Tropical Medicine said of the vaccine.
The technology used in AZD1222 has never been deployed in a licensed human vaccine before.
“We are proud to provide our CDMO services to advance AstraZeneca’s COVID-19 vaccine candidate. With this agreement, we bring to our facilities two of the five leading candidates being developed with U.S. government funding," said Robert G. Kramer Sr., president of Emergent BioSolutions.
AstraZeneca has also signed a licensing agreement with the Serum Institute of India to supply one billion doses to low- and middle-income countries. The company will provide 400 million of these doses before the year ends.
It's also building in parallel a number of supply chains across the world to bring global access to the vaccine at no profit for two billion doses.
Oxford University is set to start the later states of AZD1222 trials in many other countries.
"AstraZeneca recognizes that the vaccine may not work but is committed to progressing the clinical program with speed and scaling up manufacturing at risk," the company said.